Cargando…
Heterogeneous treatment effects of dexamethasone 12 mg versus 6 mg in patients with COVID‐19 and severe hypoxaemia—Post hoc exploratory analyses of the COVID STEROID 2 trial
BACKGROUND: Corticosteroids improve outcomes in patients with severe COVID‐19. In the COVID STEROID 2 randomised clinical trial, we found high probabilities of benefit with dexamethasone 12 versus 6 mg daily. While no statistically significant heterogeneity in treatment effects (HTE) was found in th...
Autores principales: | Granholm, Anders, Munch, Marie Warrer, Andersen‐Ranberg, Nina, Myatra, Sheila Nainan, Vijayaraghavan, Bharath Kumar Tirupakuzhi, Venkatesh, Balasubramanian, Jha, Vivekanand, Wahlin, Rebecka Rubenson, Jakob, Stephan M., Cioccari, Luca, Møller, Morten Hylander, Perner, Anders |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9874464/ https://www.ncbi.nlm.nih.gov/pubmed/36314057 http://dx.doi.org/10.1111/aas.14167 |
Ejemplares similares
-
Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia
por: Granholm, Anders, et al.
Publicado: (2022) -
Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial
por: Granholm, Anders, et al.
Publicado: (2021) -
Effects of 12 mg vs. 6 mg dexamethasone on thromboembolism and bleeding in patients with critical COVID-19 - a post hoc analysis of the randomized, blinded COVID STEROID 2 trial
por: Jonmarker, Sandra, et al.
Publicado: (2023) -
The effect of blinding on estimates of mortality in randomised clinical trials of intensive care interventions: protocol for a systematic review and meta-analysis
por: Anthon, Carl Thomas, et al.
Publicado: (2017) -
How likely are COVID-19 interventions to benefit the sickest patients?
por: Perner, Anders, et al.
Publicado: (2020)